
Diagnostic Medical (ALDMS) | Financial Analysis & Statements
Diagnostic Medical Systems S.A. | Small-cap | Healthcare
Diagnostic Medical Systems S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
53.9M
Total Liabilities
39.8M
Shareholders Equity
14.2M
Debt to Equity
2.81
Cash Flow Metrics
Revenue & Profitability Trend
Diagnostic Medical Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 46.1M | 42.2M | 35.3M | 36.3M | 32.1M |
Cost of Goods Sold | 27.7M | 26.3M | 21.4M | 22.9M | 19.4M |
Gross Profit | 18.4M | 15.8M | 13.8M | 13.3M | 12.6M |
Gross Margin % | 39.9% | 37.6% | 39.2% | 36.8% | 39.4% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | 5.6M | 5.3M |
Other Operating Expenses | 9.2M | 15.1M | 10.7M | 5.1M | -396.0K |
Total Operating Expenses | 9.2M | 15.1M | 10.7M | 10.8M | 4.9M |
Operating Income | -1.3M | -9.2M | -5.1M | -488.0K | -2.4M |
Operating Margin % | -2.9% | -21.8% | -14.5% | -1.3% | -7.3% |
Non-Operating Items | |||||
Interest Income | 243.0K | 140.0K | 33.0K | 0 | 4.0K |
Interest Expense | 740.0K | 456.0K | 220.0K | 296.0K | 934.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -2.6M | -9.8M | -6.6M | -2.6M | -4.2M |
Income Tax | 205.0K | 2.0K | 20.0K | 0 | -1.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -2.8M | -5.0M | -9.0M | -4.7M | -5.5M |
Net Margin % | -6.1% | -11.9% | -25.4% | -13.0% | -17.3% |
Key Metrics | |||||
EBITDA | 299.0K | -5.1M | -820.0K | 3.2M | -167.0K |
EPS (Basic) | €-0.14 | €-0.28 | €-0.42 | €-0.24 | €-0.33 |
EPS (Diluted) | €-0.14 | €-0.28 | €-0.42 | €-0.24 | €-0.33 |
Basic Shares Outstanding | 20447600 | 17463415 | 16120556 | 16120556 | 16120556 |
Diluted Shares Outstanding | 20447600 | 17463415 | 16120556 | 16120556 | 16120556 |
Income Statement Trend
Diagnostic Medical Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 5.3M | 4.8M | 4.4M | 4.2M | 1.7M |
Short-term Investments | 711.0K | 959.0K | 409.0K | - | - |
Accounts Receivable | 7.5M | 6.5M | 5.9M | 6.8M | 6.5M |
Inventory | 14.4M | 16.0M | 13.0M | 11.9M | 12.9M |
Other Current Assets | 233.0K | 410.0K | 40.0K | 66.0K | 92.0K |
Total Current Assets | 30.3M | 31.7M | 29.0M | 28.1M | 24.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 348.0K | 347.0K | 5.8M | 1.6M | 1.6M |
Goodwill | 26.8M | 18.4M | 8.7M | 17.0M | 18.2M |
Intangible Assets | 10.7M | 9.1M | 6.7M | 8.9M | 10.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | -9.0K | 1.0K | -1.0K |
Total Non-Current Assets | 23.6M | 19.5M | 24.9M | 25.0M | 21.4M |
Total Assets | 53.9M | 51.1M | 53.9M | 53.0M | 45.8M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 10.8M | 10.4M | 11.0M | 9.7M | 8.0M |
Short-term Debt | 8.6M | 6.9M | 3.6M | 5.8M | 4.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 3.4M | 2.9M | 3.3M | 4.5M | 4.5M |
Total Current Liabilities | 23.5M | 22.0M | 24.4M | 21.7M | 18.1M |
Non-Current Liabilities | |||||
Long-term Debt | 11.5M | 13.2M | 10.4M | 10.0M | 10.2M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | - | 1.0K | -1.0K | 531.0K | 1.0K |
Total Non-Current Liabilities | 16.3M | 15.4M | 11.3M | 10.9M | 10.6M |
Total Liabilities | 39.8M | 37.4M | 35.7M | 32.6M | 28.6M |
Equity | |||||
Common Stock | 24.7M | 20.9M | 19.1M | 19.1M | 19.1M |
Retained Earnings | -2.9M | -4.9M | -6.8M | -3.9M | -5.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 14.2M | 13.7M | 18.2M | 20.4M | 17.2M |
Key Metrics | |||||
Total Debt | 20.1M | 20.1M | 14.0M | 15.8M | 14.8M |
Working Capital | 6.8M | 9.7M | 4.6M | 6.4M | 6.4M |
Balance Sheet Composition
Diagnostic Medical Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -2.8M | -5.0M | -9.0M | -4.7M | -5.5M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 3.6M | 75.0K | 325.0K | -2.2M | 1.2M |
Operating Cash Flow | 3.2M | -4.6M | -4.7M | -6.9M | -4.3M |
Investing Activities | |||||
Capital Expenditures | -3.5M | -2.6M | -4.5M | -2.0M | -3.1M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | -2.6M | -1.3M | - |
Investment Sales | - | - | - | 165.0K | 2.0K |
Investing Cash Flow | -2.9M | -1.5M | -5.7M | -2.7M | 4.6M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 3.5M | 5.4M | 5.7M | 8.4M | 8.0M |
Debt Repayment | -3.0M | -2.0M | -8.6M | -2.9M | -7.3M |
Financing Cash Flow | 627.0K | 3.5M | 3.1M | 6.2M | 1.0M |
Free Cash Flow | 30.0K | -4.4M | -4.2M | -7.0M | -6.8M |
Net Change in Cash | 933.0K | -2.6M | -7.3M | -3.3M | 1.3M |
Cash Flow Trend
Diagnostic Medical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-9.57
Forward P/E
33.50
Price to Book
2.18
Price to Sales
0.74
Profitability Ratios
Profit Margin
-5.90%
Operating Margin
1.90%
Return on Equity
-20.20%
Return on Assets
-0.94%
Financial Health
Current Ratio
1.29
Debt to Equity
141.76
Beta
0.88
Per Share Data
EPS (TTM)
€-0.13
Book Value per Share
€0.62
Revenue per Share
€2.39
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
aldms | 36.0M | -9.57 | 2.18 | -20.20% | -5.90% | 141.76 |
Guerbet S.A | 341.6M | 15.28 | 0.62 | 3.50% | 1.89% | 100.91 |
Eurobio Scientific | 253.4M | 64.87 | 1.42 | 2.26% | 2.58% | 5.46 |
Median Technologies | 87.8M | -1.75 | - | 74.31% | -109.93% | -0.98 |
Affluent Medical | 59.2M | -3.85 | 1.83 | -48.69% | -275.50% | 0.54 |
Carmat S.A | 8.6M | -0.11 | - | 100.52% | -336.56% | -1.13 |
Financial data is updated regularly. All figures are in the company's reporting currency.